Right on the heels of an FDA approval for seizure med Xcopri, South Korea’s SK Biopharmaceuticals is reportedly planning an initial public offering to raise about $850 million. The company plans to list shares in January and has chosen Citigroup and NH Investment
read moreWatch out, Amgen, Sanofi and Regeneron. Thanks to Novartis’ $9.7 billion Medicines Company buyout pact, PCSK9 competition is about to get a lot more intense. But the question remains: Can Novartis really make its heart prospect work where its two
read moreRoche’s risdiplam, a potential 2020 entrant in spinal muscular atrophy, scored a FDA priority review on Monday. Analysts expect the med to bring in blockbuster sales at peak as it challenges Biogen’s Spinraza and Novartis’ gene therapy Zolgensma. The FDA
read moreDriven by a landmark cardiovascular outcomes trial that could spell blockbuster sales for its fish-oil derivative, Vascepa, Amarin has been a darling for pharma M&A speculators. Now, after Novartis’ $9.7 billion agreement to pick up The Medicines Company, the rumor mill
read moreCDMOs are building gene therapy and viral vector manufacturing facilities left and right, but Harvard says it just isn’t enough, at least to serve the Boston biotech hub. That is why a host of public and private players is working
read moreThe company intends to file a Marketing Authorisation Application (MAA) in the first half of next year, based on Phase II and III trials. More: FDA ‘yes’ brings SK Biopharma’s seizure drug one step closer to Europe Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals